MatriSys Bioscience Announces Initiation of Corporate IND for its MSB-01 with the FDA and new Microbiome formulation IP filing
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, announced today that it has submitted a pre-IND (Investigational New Drug) meeting request …